Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H29FO4 |
| Molecular Weight | 376.4617 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
InChI
InChIKey=GAKMQHDJQHZUTJ-ULHLPKEOSA-N
InChI=1S/C22H29FO4/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-21(15,2)20(13)17(26)9-22(14,3)19(11)18(27)10-24/h4-5,7,11,13-14,16-17,19-20,24,26H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20-,21+,22+/m1/s1
DescriptionCurator's Comment: description was created based on several sources, including
http://www.druginfosys.com/Drug.aspx?DrugCode=1121&DrugName=Fluocortolone&type=1
Curator's Comment: description was created based on several sources, including
http://www.druginfosys.com/Drug.aspx?DrugCode=1121&DrugName=Fluocortolone&type=1
Fluocortolone is a topical corticosteroid (class of steroid hormones formed in the adrenal gland). Is primary indicated in condition like, Ana fissure, Dermatosis haemorrhoids, proctitis. The signs and symptoms that are produced after the acute overdosage include convulsions, respiratory arrest, allergic skin reactions. Glucocorticoids, such as fluocortolone, act through nuclear hormone receptors Schaaf and Cidlowski (2002). The two members of this family are glucocorticoid receptor (GR) type I and GR type I I. Activation of these sites alters gene expression of endogenous agents that influence immune and inflammatory responses.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Operational post-keratopasty graft tolerance due to differential HLAMatchmaker matching. | 2010-11-11 |
|
| Update on the management of chronic eczema: new approaches and emerging treatment options. | 2010-07-28 |
|
| Prevention and treatment of intertrigo in large skin folds of adults: a systematic review. | 2010-07-13 |
|
| Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010-04 |
|
| A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves' orbitopathy. | 2010-01 |
|
| Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study. | 2009-11 |
|
| [Retinochoroidopathy after intravitreal anti-VEGF treatment]. | 2009-08 |
|
| Adalimumab for the treatment of fistulas in patients with Crohn's disease. | 2009-07 |
|
| A simple and rapid ESI-LC-MS/MS method for simultaneous screening of doping agents in urine samples. | 2009-04 |
|
| Stenotrophomonas maltophilia induced post-cataract-surgery endophthalmitis: Outbreak investigation and clinical courses of 26 patients. | 2009-04 |
|
| Transrepression and transactivation potencies of inhaled glucocorticoids. | 2008-12 |
|
| Adherence to clocortolone pivalate cream 0.1% in a pediatric population with atopic dermatitis. | 2008-05 |
|
| Varicella chorioretinitis. | 2007-12 |
|
| German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). | 2007-06 |
|
| [Sudden hearing loss in a patient with a 3-mm acoustic tumor]. | 2007 |
|
| Oral and intralesional steroid therapy in giant cell granuloma. | 2006-06 |
|
| An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. | 2006-03-15 |
|
| Recurrent optic disc and retinal vasculitis in a patient with drug-induced urticarial vasculitis. | 2006 |
|
| [Ranking of systemic steroids after normal-risk keratoplasty. Results of a randomized prospective study]. | 2005-05 |
|
| Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. | 2005-04-27 |
|
| Topical FK506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study. | 2005-02 |
|
| Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. | 2004-11 |
|
| Syphilitic interstitial keratitis: treatment with immunosuppressive drug combination therapy. | 2004-07 |
|
| Childhood lichen planus with nail involvement: a case. | 2003-12-31 |
|
| [Bilateral uveitis intermedia. A 15-year clinical course]. | 2003-12 |
|
| Orbital myositis in a patient with primary biliary cirrhosis: successful treatment with methotrexate and corticosteroids. | 2003-11 |
|
| Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. | 2003-08 |
|
| An integrative approach to eczema (atopic dermatitis). | 2003-02-25 |
|
| A case of cutaneous delayed-type allergy to oral dexamethasone and to betamethasone. | 2002 |
|
| Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. | 2001-06 |
|
| Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial. | 2001-04 |
|
| Contact allergies to topical corticosteroids: 10 cases of contact dermatitis. | 1991-08 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QH02AB03
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-ATC |
S01CA04
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-ATC |
C05AA08
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-VATC |
QD07AC05
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-VATC |
QC05AA08
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-ATC |
D07XC05
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-ATC |
D07BC03
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-ATC |
D07CC06
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-ATC |
H02AB03
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-VATC |
QD07CC06
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-VATC |
QD07BC03
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-ATC |
D07AC05
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
||
|
WHO-VATC |
QS01CA04
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB08971
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
4463
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB07717MIG
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
D005448
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
FLUOCORTOLONE
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
1206
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
DTXSID00861835
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
C80819
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
65VXC1MH0J
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
1904
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
100000080734
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
m5454
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | Merck Index | ||
|
205-811-5
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
9053
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL251634
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY | |||
|
152-97-6
Created by
admin on Mon Mar 31 17:56:48 GMT 2025 , Edited by admin on Mon Mar 31 17:56:48 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
